Arikayce inhaled liposomal amikacin developer Insmed Incorporated has announced the appointment of Eugene Sullivan, a former FDA Deputy Director of the Division of Pulmonary and Allergy Products, as Chief Medical and Scientific Officer. Sullivan has also served as Chief Medical Officer of United Therapeutics and VP, Global Regulatory Affairs at Astra Zeneca.
Insmed CEO Will Lewis commented, “I am extremely pleased to welcome Gene to the Insmed team. His broad clinical and regulatory experience with both development stage and commercial products will be very valuable to Insmed. Gene is actively involved as an author, lecturer and advisor on medical and regulatory matters affecting orphan drugs and pulmonary diseases. His experience will provide new insight and valuable perspective as we advance Arikayce, INS1009 and our other pipeline candidates while building Insmed into a leading biopharmaceutical company.”
Sullivan said, “It is a pleasure to join Will and the Insmed team. The company’s focus on developing and acquiring therapeutics for unmet medical needs in pulmonary and orphan diseases offers a very exciting professional opportunity. Throughout my career I have been keenly focused on delivering benefit to patients in these underserved therapeutic indications. I look forward to being a part of this dynamic leadership team as we bring new treatments to patients suffering from these serious lung diseases.”
Read the Insmed press release.
